基于血液基因表达的肾移植术后亚临床排斥无创诊断
本研究在独立多中心队列588例肾移植受者中验证六基因耐受评分与免疫事件及排斥风险的相关性,并基于441例方案活检患者中45例活检证实的亚临床排斥(SCR)将评分精炼为仅含AKR1C3和TCL1A两基因加四项临床参数的SCR评分,该评分识别不发生SCR患者的C统计量为0.864、阴性预测值为98.3%,并在外部实验室以qPCR和NanoString两种方法及447例独立多中心队列中完成验证。
要点
- 六基因耐受评分在45例活检证实的SCR患者中显著降低。
- 精炼SCR评分含AKR1C3、TCL1A两基因及四项临床参数。
- 精炼SCR评分识别不发生SCR者C统计量0.864、阴性预测值98.3%。
核心结论
- 精炼SCR评分可提高SCR检出,用于更密切的无创监测,从而对SCR病变进行早期治疗,尤其适用于DSA阳性及免疫抑制减量期间的患者。
研究设计与样本
- 独立多中心队列研究,纳入588例肾移植受者,移植后一年配对血液样本与活检,以qPCR和NanoString方法检测评分。
- 441例患者接受方案活检,其中45例为活检证实的亚临床排斥(SCR)。
- 精炼SCR评分在外部实验室以qPCR和NanoString两种方法、447例来自独立多中心队列的患者中验证。
主要发现
- 45例活检证实的SCR患者六基因耐受评分显著降低。
- 精炼SCR评分识别不发生SCR患者的C统计量为0.864,阴性预测值为98.3%。
- 该评分可重新分类DSA存在与抗体介导排斥组织学诊断不一致的患者,而肾功能无此作用。
关键数值与推荐
- 精炼SCR评分由AKR1C3和TCL1A两基因及四项临床参数(既往排斥经历、既往移植、受者性别和他克莫司摄取)构成。
- 精炼SCR评分识别不发生SCR患者的C统计量为0.864,阴性预测值为98.3%。
临床怎么用
- 作者认为精炼SCR评分可提高SCR检出,用于更密切的无创监测,从而对SCR病变进行早期治疗,尤其适用于DSA阳性及免疫抑制减量期间的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We previously established a six-gene-based blood score associated with operational tolerance in kidney transplantation which was decreased in patients developing anti-HLA donor-specific antibodies (DSA). Herein, we aimed to confirm that this score is associated with immunological events and risk of rejection. We measured this using quantitative PCR (qPCR) and NanoString methods from an independent multicenter cohort of 588 kidney transplant recipients with paired blood samples and biopsies at one year after transplantation validating its association with pre-existing and de novo DSA. From 441 patients with protocol biopsy, there was a significant decrease of the score of tolerance in 45 patients with biopsy-proven subclinical rejection (SCR), a major threat associated with pejorative allograft outcomes that prompted an SCR score refinement. This refinement used only two genes, AKR1C3 and TCL1A, and four clinical parameters (previous experience of rejection, previous transplantation, sex of recipient and tacrolimus uptake). This refined SCR score was able to identify patients unlikely to develop SCR with a C-statistic of 0.864 and a negative predictive value of 98.3%. The SCR score was validated in an external laboratory, with two methods (qPCR and NanoString), and on 447 patients from an independent and multicenter cohort. Moreover, this score allowed reclassifying patients with discrepancies between the DSA presence and the histological diagnosis of antibody mediated rejection unlike kidney function. Thus, our refined SCR score could improve detection of SCR for closer and noninvasive monitoring, allowing early treatment of SCR lesions notably for patients DSA-positive and during lowering of immunosuppressive treatment.
引用
- Danger R, Le Berre L, Cadoux M, et al. Subclinical rejection-free diagnostic after kidney transplantation using blood gene expression. Kidney Int. 2023. PMID: 36990211. doi:10.1016/j.kint.2023.03.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。